Related Experiment Video
Updated: Feb 15, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
Published on: December 2, 2016
Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation
Marika Milan1, Valentina Pace1, Fabio Maiullari1,2
1Institute of Cell Biology and Neurobiology (IBCN), National Research Council of Italy (CNR), Monterotondo Scalo, Rome, 00015, Italy.
Insights
Histone deacetylase inhibitor Givinostat reduced cardiac fibrosis and improved heart function in a mouse model of myocardial infarction. This epigenetic therapy shows promise for treating cardiovascular diseases (CVDs).
Area of Science:
- Cardiovascular Research
- Epigenetics
- Pharmacology
Background:
- Cardiovascular diseases (CVDs) represent a significant global health burden, with heart failure as a common outcome.
- Current treatments struggle to halt the structural changes leading to heart failure.
- Epigenetics, particularly histone modifications, plays a role in CVDs, but therapeutic interventions are limited.
Purpose of the Study:
- To investigate the therapeutic potential of the histone deacetylase inhibitor, Givinostat, in a mouse model of acute myocardial infarction.
- To elucidate the mechanisms by which Givinostat impacts cardiac tissue and vascular function post-myocardial infarction.
Main Methods:
- Utilized a mouse model of acute myocardial infarction.
- Administered the histone deacetylase inhibitor, Givinostat.
- Assessed changes in endothelial-to-mesenchymal transition, inflammation, cardiac fibrosis, vascular apoptosis, and cardiac performance.
Main Results:
- Givinostat treatment decreased endothelial-to-mesenchymal transition and inflammation.
- The drug reduced cardiac fibrosis and improved overall heart performance.
- Givinostat protected blood vessels from apoptosis via modulation of cardiac fibroblasts on endothelial cells.
Conclusions:
- Givinostat demonstrates a protective effect in a mouse model of myocardial infarction.
- The drug's mechanisms involve reducing fibrosis, inflammation, and vascular apoptosis.
- Givinostat shows potential as a novel therapeutic agent for cardiovascular diseases.
Abstract:
Cardiovascular diseases (CVDs) are a major burden on the healthcare system: indeed, over two million new cases are diagnosed every year worldwide. Unfortunately, important drawbacks for the treatment of these patients derive from our current inability to stop the structural alterations that lead to heart failure, the common endpoint of many CVDs. In this scenario, a better understanding of the role of epigenetics - hereditable changes of chromatin that do not alter the DNA sequence itself - is warranted. To date, hyperacetylation of histones has been reported in hypertension and myocardial infarction, but the use of inhibitors for treating CVDs remains limited. Here, we studied the effect of the histone deacetylase inhibitor Givinostat on a mouse model of acute myocardial infarction. We found that it contributes to decrease endothelial-to-mesenchymal transition and inflammation, reducing cardiac fibrosis and improving heart performance and protecting the blood vessels from apoptosis through the modulatory effect of cardiac fibroblasts on endothelial cells. Therefore, Givinostat may have potential for the treatment of CVDs.
Related Concept Videos
Nucleosome Remodeling
Nucleosome remodeling complex
Eukaryotic cells have specialized enzymes called ATP-dependent nucleosome remodeling enzymes. These enzymes...
Enteric Nervous System: Regulation of GI Motor Activity
During periods of fasting, the ENS initiates the migrating myoelectric complex, a...
GPCRs Regulate Adenylyl Cylase Activity
GTPases and their Regulation
Large G-proteins,...
Bone Remodeling
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...

